Fight for Sight response to the Spark Therapeutics price for Luxturna

04 January 18

written by:

Press Office

(more articles)

Fight for Sight comment

George McNamara, Director of Research, Policy and Innovation of Fight for Sight, the eye research charity, comments that: “Gene therapy is a novel technique which holds the potential to deliver new treatments for those living with sight loss. The approval of Luxturna in the US highlights the importance of ensuring that as more gene therapies come into effect here in the UK, that industry and government work together to guarantee that these ground breaking treatments are accessible to the patients.”

Share this page